CTLA4 and cancer: In the past few years, cancer immunotherapy has made leaps and bounds due to a better understanding of immune surveillance and usage of immune checkpoints including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1).